Recombinant Human Leukocyte immunoglobulin-like receptor subfamily B member 5 (LILRB5)

What is the genomic location and structure of LILRB5?

The LILRB5 gene is located within a gene cluster at chromosomal region 19q13.4 . Structurally, LILRB5 belongs to the subfamily B class of LIR receptors, characterized by:

• Two or four extracellular immunoglobulin domains that function in ligand recognition

• A transmembrane domain

• Two to four cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that mediate inhibitory signaling

This structural organization defines LILRB5 as an inhibitory receptor. Multiple transcript variants encoding different isoforms have been found for this gene, indicating potential diversity in function based on alternative splicing . Recent studies have also identified a novel hybrid gene formed between LILRB5 and LILRB3, designated LILRB5-3, which combines the extracellular domain of LILRB5 with a partial LILRB3 intracellular domain containing three ITIMs . This hybrid gene may confer novel signaling properties beyond those of the canonical LILRB5.

What are the known ligands for LILRB5?

LILRB5 has been an orphan receptor whose ligands remained unidentified for some time. Recent research has revealed that LILRB5 binds specifically to HLA-class I heavy chains, particularly HLA-B27 free heavy chain (FHC) dimers . This binding appears to be selective, as other HLA-class I molecules did not stain LILRB5-transfected 293T cells. The interaction between LILRB5 and B27 dimers can be blocked with the class I heavy chain antibody HC10 and anti-LILRB5 antisera, confirming specificity . Co-immunoprecipitation studies have further validated that HLA-B7 and B27 heavy chains interact with LILRB5 in transduced B cell and rat basophil cell lines . This unique binding specificity for HLA-class I heavy chains likely results from differences in the D1 and D2 immunoglobulin-like binding domains of LILRB5, which are distinct from other LILR family members that bind to β2m-associated HLA-class I .

How does LILRB5 signaling influence immune cell function?

LILRB5 contains cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that typically mediate inhibitory signaling in immune cells. When LILRB5 engages its ligands, these ITIMs become phosphorylated and recruit phosphatases that downregulate activating signaling pathways . Interestingly, crosslinking of LILRB5 on T cells has been shown to increase proliferation of cytotoxic T cells, but not helper T cells, suggesting cell-type specific effects of LILRB5 signaling . In the context of mycobacterial exposure, LILRB5 transcription is significantly upregulated, and the receptor can trigger signaling through direct engagement with mycobacteria . The novel LILRB5-3 hybrid gene identified in some individuals exhibits altered intracellular domains, containing three ITIMs derived from LILRB3, which suggests potential modifications to the signaling capacity of this variant receptor . This diversity in signaling properties likely contributes to the fine-tuning of immune responses in different contexts.

How does LILRB5 influence immune responses to mycobacterial infections?

LILRB5 has emerged as a potentially important receptor in mycobacterial recognition and immune regulation. Transcriptional profiling has shown that LILRB5 expression is significantly upregulated following exposure to mycobacteria, suggesting a role in the immune response to these pathogens . Functional studies have demonstrated that LILRB5 can trigger signaling through direct engagement of mycobacteria, as shown in transfectant cells incorporating a reporter system .

The role of LILRB5 in T cell responses to mycobacteria represents a novel finding, as LILRB5 was previously thought to be expressed primarily on myeloid cells. Crosslinking experiments have shown that engagement of LILRB5 on T cells increases proliferation specifically of cytotoxic T cells, but not helper T cells . This selective effect on cytotoxic T cells may be particularly relevant for immunity against intracellular pathogens like Mycobacterium tuberculosis, where CD8+ T cell responses contribute to pathogen control.

Given that other LILR family members have been shown to influence the antigen presenting phenotype of monocytic cells and shape T cell responses in infections such as Mycobacterium leprae, the upregulation and direct mycobacterial engagement of LILRB5 suggests it may play an analogous role in tuberculosis pathogenesis or immunity .

What methods are most effective for studying LILRB5 expression and function?

Several complementary methodologies have proven effective for investigating LILRB5:

• Gene Expression Analysis:

  • Real-time PCR for transcriptional profiling of LILRB5 in response to stimuli

  • cDNA cloning to identify LILRB5 isoforms and hybrid genes

• Protein Detection Systems:

  • Generation of C-terminal eGFP and N-terminal FLAG-tagged fusion constructs for monitoring LILRB5 expression

  • Anti-LILRB5 antisera for specific detection and blocking of LILRB5

  • Flow cytometry with specific antibodies (e.g., anti-LILRB5 clone 395239) for cell surface expression analysis

• Functional Analysis:

  • Tetramer staining to assess LILRB5 binding to potential ligands

  • Co-immunoprecipitation to confirm protein-protein interactions

  • Transfection of 293T cells with LILRB5 constructs for surface expression studies

  • Lentiviral transduction for stable expression in various cell lines (e.g., 221, 220, RBL cells)

• Genetic Analysis:

  • Long-read sequencing for identification of hybrid genes and structural variants

  • JoGo-LILR tool for copy number variation analysis in population studies

These methods can be combined to provide comprehensive insights into LILRB5 biology, from genetic variation to protein expression and functional consequences.

What is the significance of the LILRB5-3 hybrid gene and how can it be detected?

The LILRB5-3 hybrid gene represents an important discovery in LILR biology with potential functional implications. This hybrid gene results from a structural rearrangement where LILRB5 exons 1-12 are fused with LILRB3 exons 12-13, accompanied by the loss of LILRA6 . The hybrid junction is located within the intracellular domain, resulting in an LILRB5 extracellular domain fused to a partial LILRB3 intracellular domain containing three immunoreceptor tyrosine-based inhibitory motifs (ITIMs) .

Significance:

• Creates a novel receptor with potentially altered signaling properties

• Preserves the ligand-binding specificity of LILRB5 while incorporating LILRB3 signaling elements

• May contribute to functional diversity in the LILR family

• Present in specific human populations (e.g., CEU population)

Detection Methods:

• Long-read sequencing: The most definitive method for identifying the LILRB5-3 hybrid gene

• PCR with specific primers:

  • Forward primer targeting LILRB5: 5'-CCTGCACAGCTGAGTCCAGT-3'

  • Reverse primer targeting LILRB3: 5'-TTAGTCATCTTTGAGTCAGGTGAG-3'

• JoGo-LILR tool: Applied to CRAM files for detection in population genomics studies

• Flow cytometry: Using anti-LILRB5 antibodies to detect surface expression of the hybrid protein in transfected cells

Transcription and translation of the LILRB5-3 hybrid gene have been verified, confirming that this is not merely a genomic rearrangement but results in the expression of a functional hybrid protein with potentially novel immunoregulatory properties .

How can recombinant LILRB5 proteins be engineered for functional studies?

Engineering recombinant LILRB5 proteins for functional studies requires careful consideration of protein domains, tags, and expression systems. Based on published methodologies, the following approaches have proven effective:

Fusion Tag Strategies:

• N-terminal FLAG tags for detection and purification

• C-terminal eGFP tags for visualization and tracking

• Combined tagging approaches (e.g., FLAG-LILRB5-eGFP) for multiple detection methods

Expression Vector Systems:

• pHR-SIN lentiviral vectors for stable cell line transduction

• Plasmid vectors for transient transfection studies

Expression Systems:

• 293T cells: Reliable for surface expression of LILRB5

• B lymphoblast cell lines (e.g., LCL.721.221): For studying interactions with HLA molecules

• Rat basophil RBL cell line: Alternative system for LILRB5 expression studies

Design Considerations:

• Include the complete extracellular domain for ligand binding studies

• Preserve transmembrane regions for proper membrane localization

• Maintain intact ITIMs for signaling studies

• Consider domain-swapping experiments to identify functional regions

Detection Methods:

• Immunofluorescence microscopy for localization studies

• FACS analysis with anti-FLAG or anti-LILRB5 antibodies

• Western blotting of immunoprecipitates for protein interaction studies

Special considerations include the potential for cell-type specific differences in surface expression, as LILRB5 may be retained intracellularly in some cell types despite high expression levels . Additionally, researchers should validate the specificity of any engineered constructs through binding assays with known ligands such as HLA-B27 FHC dimers .

What techniques are most suitable for studying LILRB5 interactions with ligands?

Several complementary techniques have been successfully employed to investigate LILRB5 interactions with its ligands, particularly HLA-class I heavy chains:

• Tetramer Staining:

  • HLA-class I tetramers (especially B27 FHC dimers) can be used to stain LILRB5-transfected cells

  • Specificity can be confirmed by blocking with anti-LILRB5 antisera or HC10 antibody

  • Suitable for both transfected cell lines and primary monocytes expressing LILRB5

• Co-immunoprecipitation:

  • Immunoprecipitation with anti-HLA-class I heavy chain antibody (HC10) followed by western blot with anti-FLAG antibody (for FLAG-tagged LILRB5)

  • Reciprocal approach: immunoprecipitation with anti-FLAG followed by western blot with HC10

  • Effective for confirming physical interactions between LILRB5 and HLA heavy chains

• Flow Cytometry:

  • Multiparameter flow cytometry with anti-LILRB5 antisera or antibodies

  • Combined with cell type-specific markers (CD14, CD3, CD19, CD56) to determine expression patterns

  • Can be used to study the binding of fluorescently labeled ligands to LILRB5+ cells

• Reporter Systems:

  • Transfectant cells incorporating reporter systems (e.g., NFAT-GFP) to study signaling upon ligand engagement

  • Particularly useful for studying direct engagement of microbial components by LILRB5

• Crosslinking Experiments:

  • Using anti-LILRB5 antibodies to crosslink the receptor on T cells

  • Measuring functional outcomes such as proliferation to assess signaling consequences

Each technique offers distinct advantages and limitations, and combining multiple approaches provides the most robust evidence for specific interactions and their functional consequences.

How can the expression pattern of LILRB5 be comprehensively characterized in human tissues and cells?

Characterizing the expression pattern of LILRB5 requires a multi-faceted approach that combines transcriptional analysis, protein detection, and functional validation:

• Transcriptional Analysis:

  • Real-time PCR to quantify LILRB5 mRNA in different tissues and cell types

  • RNA-seq for genome-wide expression profiling and isoform identification

  • Single-cell RNA-seq to identify specific cell populations expressing LILRB5

• Protein Detection:

  • Flow cytometry with specific anti-LILRB5 antibodies or antisera

  • Multiparameter analysis with lineage markers (CD14, CD3, CD19, CD56) to identify expressing cell types

  • Immunohistochemistry or immunofluorescence of tissue sections

  • Western blotting of tissue or cell lysates

• Functional Validation:

  • Tetramer staining with known ligands (e.g., B27 FHC dimers) to confirm functional receptor expression

  • Signaling assays in different cell types expressing LILRB5

  • Receptor crosslinking experiments to assess functional consequences

• Genetic Approaches:

  • Analysis of LILRB5 variants and hybrid genes (e.g., LILRB5-3) in different populations

  • Correlation of expression with genetic variation

A comprehensive expression analysis would include examination of:

• Different immune cell subsets (monocytes, dendritic cells, T cells, B cells, NK cells)

• Various activation states and differentiation stages

• Tissues with immune relevance (blood, lymph nodes, spleen, thymus, mucosal tissues)

• Expression changes during infection, inflammation, or other pathological conditions

Such analyses have already revealed novel findings, such as LILRB5 expression on cytotoxic T cells, expanding our understanding of this receptor's potential roles in immunity .

What is the role of LILRB5 in mycobacterial immunity?

LILRB5 has emerged as a potentially important player in mycobacterial immunity through several mechanisms:

• Transcriptional Upregulation:

  • LILRB5 expression is significantly upregulated following exposure to mycobacteria

  • This suggests a specific response to mycobacterial components

• Direct Mycobacterial Engagement:

  • LILRB5 can trigger signaling through direct engagement of mycobacteria

  • This has been demonstrated using transfectant cells with reporter systems

  • Suggests LILRB5 may function as a pattern recognition receptor for mycobacterial components

• T Cell Function Modulation:

  • LILRB5 expression on T cells influences their response to stimulation

  • Crosslinking of LILRB5 on T cells increases proliferation specifically of cytotoxic T cells

  • This selective effect on CD8+ T cells may be particularly relevant for control of intracellular pathogens like M. tuberculosis

• Antigen Presentation Influence:

  • As observed with other LILR family members, LILRB5 may modulate the antigen presenting phenotype of monocytic cells

  • This could shape subsequent T cell responses in mycobacterial infections, similar to what has been observed with M. leprae

The discovery of LILRB5 expression on T cells and its ability to directly engage mycobacteria represents a novel pathway in mycobacterial immunity that warrants further investigation. Understanding how LILRB5 integrates with other immune receptors in the context of mycobacterial infection could provide insights into tuberculosis pathogenesis and potential therapeutic targets.

How do genetic variations in the LILRB5 gene influence its function?

The LILR gene cluster exhibits significant genetic diversity within and between human populations, and LILRB5 is no exception. Multiple transcript variants encoding different isoforms have been found for the LILRB5 gene, suggesting functional diversity arising from alternative splicing .

The most striking genetic variation involving LILRB5 is the formation of the LILRB5-3 hybrid gene, which has been detected in specific human populations, including the CEU (Utah residents with Northern and Western European ancestry) population . This structural rearrangement results in a hybrid protein with the extracellular domain of LILRB5 fused to a partial intracellular domain of LILRB3 containing three ITIMs, potentially conferring novel signaling properties .

Copy number variations (CNVs) also occur within the LILR region, and specialized tools like JoGo-LILR have been developed for CN calling in this complex genomic region . These CNVs may influence receptor expression levels or generate novel fusion proteins with altered functions.

The unique binding specificity of LILRB5 for HLA-class I heavy chains, particularly B27 dimers, likely results from sequence variations in the D1 and D2 immunoglobulin-like binding domains compared to other LILR family members . These variations determine ligand specificity and ultimately influence the biological functions of LILRB5 in different immunological contexts.

What is the potential relevance of LILRB5 in autoimmune and inflammatory conditions?

LILRB5's functions and interactions suggest several potential roles in autoimmune and inflammatory conditions:

• HLA-B27 Associated Diseases:

  • LILRB5 specifically binds to HLA-B27 free heavy chain dimers

  • HLA-B27 is strongly associated with spondyloarthropathies, including ankylosing spondylitis

  • LILRB5 may modulate immune responses to HLA-B27-presented antigens or regulate responses to B27 misfolding

• Dysregulated T Cell Responses:

  • LILRB5 crosslinking increases proliferation of cytotoxic T cells

  • Abnormal LILRB5 expression or function could potentially contribute to dysregulated cytotoxic T cell responses in autoimmunity

  • The selective effect on CD8+ but not CD4+ T cells suggests a specific role in modulating cytotoxic responses

• Genetic Variation Impact:

  • The LILRB5-3 hybrid gene present in certain populations may alter signaling properties

  • This could potentially modify susceptibility to autoimmune or inflammatory conditions

  • Population-specific genetic variants might explain differences in disease prevalence or presentation

• Mycobacteria-Associated Inflammation:

  • LILRB5's role in mycobacterial immunity suggests potential relevance to granulomatous inflammation

  • Could be important in inflammatory conditions with suspected mycobacterial triggers

  • May play a role in balancing protective immunity versus immunopathology

Future research investigating LILRB5 expression, genetic variation, and function in patients with autoimmune and inflammatory conditions could provide valuable insights into disease mechanisms and potentially identify new therapeutic targets. The specific interaction with HLA-B27 makes spondyloarthropathies a particularly promising area for LILRB5 research.

How might targeting LILRB5 be exploited for therapeutic purposes?

Based on our understanding of LILRB5 biology, several therapeutic strategies could potentially be developed:

• Modulating T Cell Responses:

  • Agonists to enhance LILRB5 signaling could potentially dampen excessive cytotoxic T cell responses in autoimmunity

  • Antagonists might enhance cytotoxic T cell responses in cancer immunotherapy or chronic infections

  • Selective targeting of LILRB5 could modulate CD8+ T cells while sparing CD4+ T cell functions

• Targeting LILRB5-HLA Interactions:

  • Blocking LILRB5 interaction with HLA-B27 free heavy chain dimers might influence spondyloarthropathies

  • This approach could potentially modify disease progression in HLA-B27-associated conditions

• Enhancing Antimycobacterial Immunity:

  • Modulating LILRB5 function could potentially enhance protective immune responses against mycobacteria

  • This might be particularly relevant for tuberculosis treatment or vaccine development

• Exploiting Genetic Variation:

  • Personalized approaches based on LILRB5 genotype (e.g., presence of LILRB5-3 hybrid)

  • Population-specific therapeutic strategies targeting different LILRB5 variants

• Recombinant LILRB5 as a Therapeutic:

  • Soluble recombinant LILRB5 domains could potentially be used to modulate immune responses

  • Fusion proteins combining LILRB5 binding domains with other functional domains

Therapeutic development would require deeper understanding of LILRB5 biology in different disease contexts and careful evaluation of potential off-target effects, given the expression of LILRB5 on multiple immune cell types and its diverse functions in immune regulation.

What are the key challenges in producing functional recombinant LILRB5 protein?

Producing functional recombinant LILRB5 presents several technical challenges that researchers must navigate:

• Expression System Selection:

  • Cell-type specific expression patterns affect surface localization

  • While 293T cells reliably express LILRB5 at the cell surface, other cell lines like RBL or 221 cells may retain LILRB5 intracellularly despite high expression levels

  • Selection of appropriate expression systems is critical for functional studies

• Protein Folding and Modification:

  • Proper folding of immunoglobulin domains is essential for ligand binding

  • Post-translational modifications may affect receptor function

  • The extracellular portion contains multiple Ig domains that must fold correctly

• Fusion Tag Considerations:

  • Tags may interfere with receptor function or ligand binding

  • Positioning of tags (N-terminal vs. C-terminal) can affect protein trafficking

  • Validation that tagged constructs retain native binding properties is essential

• Functional Validation:

  • Confirming that recombinant LILRB5 binds its natural ligands (HLA-B27 FHC dimers)

  • Verifying that signaling motifs (ITIMs) remain functional

  • Demonstrating biological activity in relevant assay systems

• Isoform Selection:

  • Multiple transcript variants exist for LILRB5

  • Different isoforms may have distinct functional properties

  • For the LILRB5-3 hybrid, ensuring correct fusion of domains is critical

Researchers have successfully addressed these challenges through careful design of expression constructs, appropriate tagging strategies (FLAG, eGFP), and comprehensive functional validation through binding assays and signaling studies. Understanding cell-type specific differences in LILRB5 expression and trafficking is particularly important for interpreting experimental results.

What are the most promising future directions for LILRB5 research?

Based on current knowledge, several promising research directions for LILRB5 emerge:

• Expanded Functional Characterization:

  • Further investigation of LILRB5's role in T cell responses, particularly in cytotoxic T cells

  • Exploration of additional ligands beyond HLA-class I heavy chains

  • Deeper understanding of signaling pathways downstream of LILRB5 in different cell types

• Genetic Variation Studies:

  • Comprehensive analysis of LILRB5 variants across human populations

  • Functional characterization of the LILRB5-3 hybrid gene and its impact on immune responses

  • Association studies linking LILRB5 genetic variation to disease susceptibility

• Disease Relevance:

  • Investigation of LILRB5's role in HLA-B27-associated spondyloarthropathies

  • Exploration of LILRB5 function in mycobacterial diseases, particularly tuberculosis

  • Assessment of LILRB5 as a potential therapeutic target in autoimmune and inflammatory conditions

• Technological Advances:

  • Development of improved tools for studying LILRB5, including specific antibodies and reporter systems

  • Application of CRISPR/Cas9 gene editing to create cellular models with LILRB5 variants

  • Single-cell approaches to understand heterogeneity in LILRB5 expression and function

• Translational Applications:

  • Development of therapeutic strategies targeting LILRB5 or its interactions

  • Biomarker studies assessing LILRB5 expression or genetic variation in disease contexts

  • Potential applications in precision medicine based on LILRB5 genotype